XML 35 R26.htm IDEA: XBRL DOCUMENT
v3.22.4

Investments (Tables) | 6 Months Ended
--- | ---
Dec. 31, 2022
Equity Method Investments and Joint Ventures [Abstract] |
Schedule of Investments | Equity investments by measurement category were as follows (in thousands):
Measurement category | December 31, 2022 |  | June 30, 2022
Fair value | $ | 4,980 |  |  | $ | 9,167 |
Measurement alternative | 65,697 |  |  | 39,290 |
Equity method | 64,099 |  |  | 9,918 |
Total | $ | 134,776 |  |  | $ | 58,375 |
Schedule of Changes in Equity Investments | The following tables show a reconciliation of the changes in our equity investments (in thousands):
| Six Months Ended December 31, 2022
| Non-marketable securities |  | Marketable securities |  | Equity method investments |  | Total
Balance at the beginning of the period | $ | 39,290 |  |  | $ | 9,167 |  |  | $ | 9,918 |  |  | $ | 58,375 |
Additions to investments (1) | 17,132 |  |  | — |  |  | 57,233 |  |  | 74,365 |
Observable price adjustments on non-marketable equity securities | 9,275 |  |  | — |  |  | — |  |  | 9,275 |
Unrealized losses on marketable equity securities | — |  |  | (4,187) |  |  | — |  |  | (4,187) |
Loss attributable to equity method investments | — |  |  | — |  |  | (4,853) |  |  | (4,853) |
Foreign currency translation adjustments | — |  |  | — |  |  | 1,801 |  |  | 1,801 |
Carrying value at the end of the period | $ | 65,697 |  |  | $ | 4,980 |  |  | $ | 64,099 |  |  | $ | 134,776 |
(1)Includes equity method investment acquired and measured at fair value via our acquisition of MEDIFOX DAN. Refer to Note 12 herein.
| Six Months Ended December 31, 2021
| Non-marketable securities |  | Marketable securities |  | Equity method investments |  | Total
Balance at the beginning of the period | $ | 23,002 |  |  | $ | 29,084 |  |  | $ | 17,154 |  |  | $ | 69,240 |
Net additions (reductions) to investments (2) | 4,665 |  |  | (3,213) |  |  | — |  |  | 1,452 |
Observable price adjustments on non-marketable equity securities | 5,367 |  |  | — |  |  | — |  |  | 5,367 |
Unrealized losses on marketable equity securities | — |  |  | (7,942) |  |  | — |  |  | (7,942) |
Realized gains on marketable and non-marketable equity securities | 2,355 |  |  | 1,637 |  |  | — |  |  | 3,992 |
Impairment of investments | (209) |  |  | — |  |  | — |  |  | (209) |
Loss attributable to equity method investments | — |  |  | — |  |  | (3,300) |  |  | (3,300) |
Carrying value at the end of the period | $ | 35,180 |  |  | $ | 19,566 |  |  | $ | 13,854 |  |  | $ | 68,600 |
(2)Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest.

X
- Definition Schedule Of Changes In Equity Investments [Table Text Block] + References No definition available. + Details
Name: | rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock
Namespace Prefix: | rmd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule Of Investments [Table Text Block] + References No definition available. + Details
Name: | rmd_ScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | rmd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration